Research Analysts Offer Predictions for TPST FY2024 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – HC Wainwright boosted their FY2024 EPS estimates for shares of Tempest Therapeutics in a report released on Wednesday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.27) per share for the year, up from their prior forecast of ($1.54). HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($1.07) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.04) EPS.

TPST has been the topic of a number of other reports. Piper Sandler dropped their target price on shares of Tempest Therapeutics from $8.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday. William Blair restated an “outperform” rating on shares of Tempest Therapeutics in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $20.00.

Tempest Therapeutics Trading Down 8.3 %

Shares of NASDAQ:TPST opened at $0.89 on Friday. The company has a 50 day moving average of $1.20 and a 200-day moving average of $1.95. The firm has a market cap of $22.43 million, a P/E ratio of -0.58 and a beta of -1.78. Tempest Therapeutics has a twelve month low of $0.83 and a twelve month high of $6.00.

Institutional Trading of Tempest Therapeutics

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC raised its stake in Tempest Therapeutics by 69.2% during the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock valued at $112,000 after purchasing an additional 11,689 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Tempest Therapeutics during the 3rd quarter worth about $34,000. Dimensional Fund Advisors LP acquired a new stake in shares of Tempest Therapeutics during the 2nd quarter worth about $55,000. Empower Advisory Group LLC acquired a new stake in shares of Tempest Therapeutics during the 3rd quarter worth about $49,000. Finally, Fullcircle Wealth LLC bought a new stake in Tempest Therapeutics during the 3rd quarter worth about $87,000. 22.52% of the stock is owned by institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.